The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
This strategic collaboration will enable continued innovation in cancer care
The designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with a preserved ejection fraction
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
